<DOC>
	<DOCNO>NCT02219503</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ombitasvir/ paritaprevir/ ritonavir dasabuvir adult genotype 1b chronic hepatitis C virus ( HCV ) infection cirrhosis .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Ombitasvir/Paritaprevir/Ritonavir Dasabuvir Adults With Genotype 1b Chronic Hepatitis C Virus ( HCV ) Infection Cirrhosis</brief_title>
	<detailed_description>This multicenter study evaluate efficacy safety ombitasvir/ paritaprevir/ritonavir dasabuvir administer 12 week HCV genotype 1b ( GT1b ) -infected , treatment-na√Øve previous pegylated interferon ( pegIFN ) / ribavirin ( RBV ) treatment-experienced adult compensate cirrhosis . The duration study 36 week ( include screen period 42 day ) consist 12-week Treatment Period 24-week Post-Treatment Period participant receive study drug .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>1 . Chronic HCV genotype 1infection prior study enrollment . Chronic HCVinfection define follow : Positive antiHCV antibody ( Ab ) HCV RNA &gt; 1,000 IU/mL least 6 month Screening , positive HCV RNA antiHCV Ab time Screening ; HCV RNA &gt; 1,000 IU/mL time Screening liver biopsy consistent chronic HCVinfection ( liver biopsy perform prior enrollment evidence chronic hepatitis C disease ) . 2 . Screening laboratory result indicate HCV genotype 1binfection . 3 . Compensated cirrhosis define ChildPugh Score 5 6 Screening . 1 . Women pregnant breastfeeding . 2 . Positive test result Hepatitis B surface antigen ( HBsAg ) positive human immunodeficiency virus ( HIV ) antibody ( confirmed Western Blot ) . 3 . Any current past clinical evidence ChildPugh B C classification clinical history liver decompensation ascites ( noted physical exam ) , variceal bleeding , hepatic encephalopathy . 4 . Confirmed presence hepatocellular carcinoma indicate image technique compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) within 3 month prior Screening ultrasound perform Screening ( positive ultrasound result confirm CT scan MRI . ) 5 . Use contraindicate medication within 2 week dose 6 . Screening laboratory analysis show follow abnormal laboratory result : Calculated creatinine clearance ( use CockcroftGault method ) &lt; 30 mL/min Albumin &lt; 2.8 g/dL International normalized ratio ( INR ) &gt; 1.8 . Participants know inherited blood disorder INR &gt; 1.8 may enrol permission AbbVie Study Designated Physician . Hemoglobin &lt; 10 g/dL Platelets &lt; 25,000 cell per mm3 Total bilirubin &gt; 3.0 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Compensated Cirrhosis</keyword>
	<keyword>Cirrhotic</keyword>
	<keyword>Hepatitis C Genotype 1b</keyword>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Interferon-Free</keyword>
	<keyword>Child Pugh A</keyword>
	<keyword>Ribavirin-Free</keyword>
</DOC>